Screener
Rapport Therapeutics, Inc. RAPP Preclinical Programs External Expenses — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For The Six Months Ended June 30, 2026 | For The Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | — | — | $20,000 | — |
| Operating expenses | ||||
| Research and development | 51,414 | 22,680 | 84,130 | 42,252 |
| Selling, general and administrative | 9,392 | 6,816 | 20,891 | 14,352 |
| Total operating expenses | 60,806 | 29,496 | 105,021 | 56,604 |
| Loss from operations | (60,806) | (29,496) | (85,021) | (56,604) |
| Other income: | ||||
| Interest income | 4,191 | 2,764 | 8,549 | 5,809 |
Item 1. Financial Statements.
FAQ
- What is Rapport Therapeutics, Inc.'s preclinical programs external expenses — research and development expense?
- Rapport Therapeutics, Inc. (RAPP) reported preclinical programs external expenses — research and development expense of $4.87M in Q2 2026.
- How has Rapport Therapeutics, Inc.'s preclinical programs external expenses — research and development expense changed year-over-year?
- Rapport Therapeutics, Inc.'s preclinical programs external expenses — research and development expense increased by 3.1% year-over-year, from $4.72M to $4.87M.
- What is the long-term trend for Rapport Therapeutics, Inc.'s preclinical programs external expenses — research and development expense?
- Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s preclinical programs external expenses — research and development expense has grown at a 61.7% compound annual growth rate (CAGR), from $6.34M to $16.57M.
- What does preclinical programs external expenses — research and development expense mean?
- This metric represents the external costs incurred for research and development activities specifically associated with the company's preclinical-stage drug discovery programs. It captures third-party expenditures such as contract research organization fees, laboratory services, and materials required to advance therapeutic candidates toward clinical trials. Monitoring this expense provides insight into the capital intensity and investment pace of the company's early-stage pipeline development.
Ask your AI about Rapport Therapeutics, Inc.'s preclinical programs external expenses — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude